Capio La Croix Du Sud

The medical center is at the forefront of research in thromboprophylaxis for patients with advanced germ cell tumors of good or intermediate prognosis. The focus is on preventing venous thromboembolic events (VTE) in patients undergoing first-line cisplatin-based chemotherapy who are at risk due to elevated baseline LDH, BSA > 1.9, or RPLN > 5 cm.

• Venous Thromboembolism Prevention
• Germ Cell Tumor Management
• Cisplatin-based Chemotherapy

This research contributes to enhancing patient outcomes by reducing the incidence of thromboembolic complications, thereby improving the overall treatment efficacy for germ cell tumors.

Specializing in high-risk and locally advanced prostate cancer, the center is exploring the efficacy of peri-operative darolutamide in conjunction with surgery. The aim is to improve non-curable progression-free survival compared to surgery alone, offering new hope for patients with challenging prognoses.

• Peri-operative darolutamide
• High-risk Prostate Cancer
• Locally Advanced Cancer Management

Through this research, the center is paving the way for more effective treatment protocols that could significantly alter the standard care practices for prostate cancer.

The center is conducting pivotal research on the impact of furosemide on the residual fragment rate post flexible ureteroscopy for kidney stone destruction. This study aims to enhance the stone-free rate three months after the procedure, potentially revolutionizing post-operative care.

• Furosemide Efficacy
• Flexible Ureteroscopy
• Kidney Stone Treatment

By improving the outcomes of kidney stone treatments, the center is contributing to less invasive and more effective management strategies for patients.

Focusing on triple negative breast cancer with residual disease post-neoadjuvant chemo-immunotherapy, the center is evaluating the efficacy of post-operative capecitabine combined with pembrolizumab. This research aims to improve invasive disease-free survival rates.

• Capecitabine and Pembrolizumab Combination
• Post-operative Cancer Therapy
• Triple Negative Breast Cancer

Through these efforts, the center is advancing therapeutic options for a particularly aggressive form of breast cancer, offering new avenues for patient care and survival.